Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

(2021) Alexander M. Menzies et al.   NATURE MEDICINE

Learning from clinical trials of neoadjuvant checkpoint blockade

(2020) Judith M. Versluis et al.   NATURE MEDICINE

An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions

(2020) Cecilia A. Larocca et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers

(2020) Mattia Garutti et al.   Cancers

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

The promise of neoadjuvant immunotherapy and surgery for cancer treatment

(2019) Jake S O'Donnell et al.   CLINICAL CANCER RESEARCH

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

(2019) Rodabe N Amaria et al.   LANCET ONCOLOGY

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

(2019) Georgina V Long et al.   LANCET ONCOLOGY

Neoadjuvant therapy for melanoma: is it ready for prime time?

(2019) Beth Helmink et al.   LANCET ONCOLOGY

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

(2019) Robert H. I. Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) O Michielin et al.   ANNALS OF ONCOLOGY

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

(2018) Rodabe N Amaria et al.   LANCET ONCOLOGY

1246PDTalimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study

(2018) H Gogas et al.   ANNALS OF ONCOLOGY

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Risk factors for positive or equivocal margins after wide local excision of 1345 cutaneous melanomas

(2017) Christopher J. Miller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

(2008) Alexander MM Eggermont et al.   LANCET